Time course of ozone-induced changes in breathing pattern in healthy exercising humans.
We examined the time course of O3-induced changes in breathing pattern in 97 healthy human subjects (70 men and 27 women). One- to five-minute averages of breathing frequency (f(B)) and minute ventilation (Ve) were used to generate plots of cumulative breaths and cumulative exposure volume vs. time and cumulative exposure volume vs. cumulative breaths. Analysis revealed a three-phase response; delay, no response detected; onset, f(B) began to increase; response, f(B) stabilized. Regression analysis was used to identify four parameters: time to onset, number of breaths at onset, cumulative inhaled dose of ozone at onset of O3-induced tachypnea, and the percent change in f(B). The effect of altering O3 concentration, Ve, atropine treatment, and indomethacin treatment were examined. We found that the lower the O3 concentration, the greater the number of breaths at onset of tachypnea at a fixed ventilation, whereas number of breaths at onset of tachypnea remains unchanged when Ve is altered and O3 concentration is fixed. The cumulative inhaled dose of O3 at onset of tachypnea remained constant and showed no relationship with the magnitude of percent change in f(B). Atropine did not affect any of the derived parameters, whereas indomethacin did not affect time to onset, number of breaths at onset, or cumulative inhaled dose of O3 at onset of tachypnea but did attenuate percent change in f(B). The results are discussed in the context of dose response and intrinsic mechanisms of action.
Schelegle
Edward S
ES
Dept. of Anatomy, Physiology, and Cell Biology, School of Veterinary Medicine, Univ. of California, One Shields Ave., Davis, CA 95616, USA. esschelegle@ucdavis.edu
Walby
William F
WF
Adams
William C
WC
D000293:Adolescent; D000328:Adult; D000393:Air Pollutants / Q000009:adverse effects*; D001285:Atropine / Q000494:pharmacology; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D015444:Exercise / Q000502:physiology*; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000494:pharmacology; D010126:Ozone / Q000009:adverse effects*; D012120:Respiration Disorders / Q000139:chemically induced; D015656:Respiratory Mechanics / Q000187:drug effects* / Q000502:physiology*; D013997:Time Factors; D014797:Vital Capacity / Q000187:drug effects / Q000502:physiology
D000393:Air Pollutants; D016861:Cyclooxygenase Inhibitors; D018727:Muscarinic Antagonists; D010126:Ozone; D001285:Atropine; D007213:Indomethacin